One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States

Background—Atherothrombosis is the underlying cause of cardiovascular, cerebrovascular, and peripheral arterial disease and is the leading cause of death in the industrialized world. The objectives of the present study are (1) to examine the annual costs associated with vascular events and interventions that require hospitalization, as well as long-term medication use for the management of associated risk factors, in a US population of outpatients with multiple atherothrombotic risk factors or a history of symptomatic disease and (2) to compare costs across patient subgroups defined according to specific arterial bed(s) affected and the number of affected arterial beds. Methods and Results—The international REduction of Atherothrombosis for Continued Health (REACH) Registry enrolled outpatients ≥45 years of age who had established coronary artery, cerebrovascular, or peripheral artery disease or ≥3 atherothrombotic risk factors. Data on risk factors, associated medications, and vascular hospitalizations and interventions were collected. Of the total 68 236-patient REACH cohort, 25 763 were enrolled from US sites. Complete 1-year data were available for 23 974 (93%) of the US patients. Annualized medication costs ranged from $2401 to $3481. Mean annual hospitalization costs per patient were $1344, $2864, $4824, and $8155 for patients with 0 (n=6145), 1 (n=14 353), 2 (n=3106), and 3 (n=370) affected arterial beds at baseline (P<0.0001 for trend). Among patients with 1 affected arterial bed, mean hospitalization costs were $2999, $2010, and $3911 for patients with coronary artery disease (n=11 063), cerebrovascular disease (n=2613), and peripheral arterial disease (n=677), respectively. Annualized medication costs ranged from $2401 to $3481. Conclusions—These results reveal the high economic burden of atherothrombosis-related clinical events and procedures and the especially high economic burden associated with polyvascular disease.

[1]  A. Ruhparwar Spotlight: Arjang Ruhparwar, MD. Interview by Richard Hoey. , 2008, Circulation.

[2]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[3]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[4]  Deepak L. Bhatt,et al.  One-year cardiovascular event rates in outpatients with atherothrombosis. , 2007, JAMA.

[5]  Deepak L. Bhatt,et al.  The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. , 2006, American heart journal.

[6]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[7]  S. Yusuf,et al.  Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. , 2006, American heart journal.

[8]  The High Concentration of U.S. Health Care Expenditures , 2006 .

[9]  S. Yusuf,et al.  Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. , 2005, Journal of the American College of Cardiology.

[10]  Elizabeth Selvin,et al.  Prevalence of and Risk Factors for Peripheral Arterial Disease in the United States: Results From the National Health and Nutrition Examination Survey, 1999–2000 , 2004, Circulation.

[11]  H. Lazenby,et al.  Age Estimates in the National Health Accounts , 2004, Health care financing review.

[12]  I. Rubin Information Agencies: Bureau of Labor Statistics and Bureau of the Census , 2003 .

[13]  From the Centers for Disease Control and Prevention. Public health and aging: trends in aging--United States and worldwide. , 2003, JAMA.

[14]  C. Cannon,et al.  Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. , 2002, JAMA.

[15]  Eric R. Ziegel,et al.  Generalized Linear Models , 2002, Technometrics.

[16]  V. Fuster,et al.  Epidemic of cardiovascular disease and stroke: the three main challenges. Presented at the 71st scientific sessions of the American Heart Association. Dallas, Texas. , 1999, Circulation.

[17]  A. Folsom,et al.  Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. , 1998, The New England journal of medicine.

[18]  W. Kannel Risk Factors for Atherosclerotic Cardiovascular Outcomes in Different Arterial Territories , 1994, Journal of cardiovascular risk.